Schrödter et al. reported that SLC6A3 could be considered as a potential biomarker of recurrence-free survival in clear cell renal cell carcinoma, showing that associated mRNA and immunoexpression in specific regions of renal tissues could be an important clinical feature, which may even be considered as a possible therapeutic target [33]. Here, SLC6A3 is linked to clear cell renal carcinoma.